Ompa and asp14 in vaccine compositions and as diagnostic targets
US-2016146811-A1 · May 26, 2016 · US
US9945851B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9945851-B2 |
| Application number | US-201715474427-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 30, 2017 |
| Priority date | Jun 27, 2012 |
| Publication date | Apr 17, 2018 |
| Grant date | Apr 17, 2018 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Anaplasma Marginale surface protein OmpA and homologous genes from Anaplasmatacaea family members are used in compositions suitable for vaccines to treat or prevent infections caused by tick-born bacteria of the Anaplasmatacaea family. OmpA proteins or peptide fragments may be used in combination with other Anaplasmatacaea surface proteins to elicit an immune response. Furthermore, antibodies to OmpA proteins can be used in diagnostic methods to determine whether an individual has contracted an Anaplasmatacaea infection.
Opening claim text (preview).
I claim: 1. An immunogenic composition including at least one polypeptide in a vehicle or carrier suitable for administration to a subject, wherein said at least one polypeptide consists of 5 to 19 consecutive residues of SEQ ID NO:84 including SEQ ID NO: 85. 2. The immunogenic composition of claim 1 , wherein said at least one polypeptide does not consist of 16 consecutive residues of SEQ ID NO:84. 3. The immunogenic composition of claim 1 , wherein said at least one polypeptide is SEQ ID NO:78. 4. The immunogenic composition of claim 3 , wherein said at least one polypeptide is SEQ ID NO: 6 or SEQ ID NO: 77. 5. The immunogenic composition of claim 1 , wherein said at least one polypeptide is SEQ ID NO:81 or SEQ ID NO:85. 6. The immunogenic composition of claim 5 , wherein said at least one polypeptide is selected from the group consisting of SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:86, and SEQ ID NO:87. 7. A method of determining if a subject has been exposed to or is infected with an obligate intracellular Anaplasmataceae bacterium selected from the group consisting of Anaplasma phagocytophilum and Anaplasma marginale , wherein said subject is suspected of having a zoonotic disease caused by an obligate intracellular Anaplasmataceae bacterium, comprising the steps of contacting a test sample from said subject, under conditions that allow polypeptide-antibody complexes to form, with a composition that includes at least one polypeptide which consists of sixteen to nineteen consecutive residues of SEQ ID NO:84 including SEQ ID NO: 85, detecting one or more polypeptide-antibody complexes in said test sample, wherein the detection is an indication that antibodies specific for Anaplasmataceae OmpA are present in the test sample, and determining said subject has been exposed to or is infected with said Anaplasmataceae bacterium if said antibodies specific for Anaplasmataceae OmpA are present in the test sample. 8. The method of claim 7 , wherein said at least one polypeptide does not consist of 16 consecutive residues of SEQ ID NO:84. 9. The method of claim 7 , wherein said at least one polypeptide is SEQ ID NO: 6 or SEQ ID NO: 77. 10. The method of claim 7 , wherein said at least one polypeptide is selected from the group consisting of SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:86, and SEQ ID NO:87. 11. The method of claim 7 , wherein said contacting and detecting steps are performed using an assay selected from the group consisting of an immunoblot and an enzyme-linked immunosorbent assay (ELISA). 12. The method of claim 7 , wherein said subject is a cow and said zoonotic disease is bovine anaplasmosis. 13. The method of claim 7 , wherein said test sample is a body fluid selected from the group consisting of blood, plasma, serum, urine, and saliva.
Emulsions, e.g. Freund's adjuvant, MF59 · CPC title
Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title
containing a GST-tag · CPC title
Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues · CPC title
Poisoning, e.g. from bites or stings · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.